Immunosuppression and hepatocellular carcinoma

Liver Transplantation

Volumn 17, Issue SUPPL. 2, 2011, Pages

  Schlitt, Hans J ^a   Mornex, Françoise ^b   Shaked, Abraham ^c   Trotter, James F ^d  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACALCITOL; TACROLIMUS;

CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CELL INVASION; DRUG EFFECT; GRAFT RECIPIENT; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY;

CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 80053250907     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22318     Document Type: Short Survey

References (17)

1. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
2. Herman M, Weinstein T, Korzets A, Chagnac A, Ori Y, Zevin D, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14-20. (Pubitemid 32100171)
3. Schumacher G, Oidtmann M, Rosewicz S, Langrehr J, Jonas S, Mueller AR, et al. Sirolimus inhibits growth of human hepatoma cells in contrast to tacrolimus which promotes cell growth. Transplant Proc 2002; 34: 1392-1393.
4. Yokoyama I, Carr B, Saitsu H, Iwatsuki S, Starzl TE,. Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation. Cancer 1991; 68: 2095-2100.
5. Hui IC, Tung EK, Sze KM, Ching YP, Ng IO,. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int 2010; 30: 65-75.
6. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M,. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res 2004; 10: 8421-8425. (Pubitemid 40053405)
7. Shirouzu Y, Ryschich E, Salnikova O, Kerkadze V, Schmidt J, Engelmann G,. Rapamycin inhibits proliferation and migration of hepatoma cells in vitro. J Surg Res 2010; 159: 705-713.
8. Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, et al. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11: 1420-1425. (Pubitemid 40468074)
9. Semela D, Piguet AC, Kolev M, Schmitter K, Hlushchuk R, Djonov V, et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol 2007; 46: 840-848. (Pubitemid 46529039)
10. Rubio E, González J, Jimenéz M, Lucena JL, Gimenez L, Martinez Arrieta F, et al. Right adrenal metastases of hepatocarcinoma after liver transplantation: case report and literature review. Transplant Proc 2009; 41: 1067-1069.
11. Stippel DL, Kasper HU, Schleimer K, Töx U, Bangard C, Hölscher AH, Beckurts KT,. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 2005; 37: 2185-2187. (Pubitemid 40956407)
12. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J,. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005; 79: 855-857. (Pubitemid 40546211)
13. Chinnakotla S, Davis GL, Vasani S, Kim P, Tomiyama K, Sanchez E, et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009; 15: 1834-1842.
14. Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010; 89: 227-231.
15. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I,. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl 2008; 14: 633-638. (Pubitemid 351696274)
16. Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007; 83: 1162-1168. (Pubitemid 46743675)
17. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM,. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51: 1237-1243.